{
    "nctId": "NCT00938756",
    "briefTitle": "Study of Cerebrospinal Fluid Samples in Diagnosing Carcinomatous Meningitis in Patients With Cancer or Meningeal Syndrome",
    "officialTitle": "Interest of the Dosage of CA 15-3 in CSF for Diagnosing Carcinomatous Meningitis in Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Brain and Central Nervous System Tumors, Breast Cancer, Metastatic Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "N/A",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 80,
    "primaryOutcomeMeasure": "CA 15-3 levels in cerebrospinal fluid",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Meets 1 of the following criteria:\n\n  * Diagnosis of metastatic breast cancer with evidence suggestive of carcinomatous meningitis, with or without brain metastasis\n  * Other type of cancer with evidence suggestive of carcinomatous meningitis\n  * Meningeal syndrome without context of cancer\n\nPATIENT CHARACTERISTICS:\n\n* No other prior cancers\n* Not pregnant or nursing\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior intrathecal treatment\n* At least 4 weeks since prior interferon\n* No concurrent participation in another clinical trial",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}